Press Release, Helsinki, 4 September 2020 at 9.30 am (EEST)
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that BrainStim Centers, US has ordered a second Nexstim NBT® System with SmartFocus® TMS technology.
The first NBT® system was first placed for evaluation at BrainStim Centers’ clinic in Valencia, California in spring and the clinic purchased it in August. Now BrainStim Centers has ordered a second system to their other clinic in Encino, California.
Dr. Mark A. Liker from BrainStim Centers commented: “As a neurosurgeon, I recognize that the accuracy of my equipment means the difference between an effective and ineffective treatment. My patients rely on this as well. The Nexstim SmartFocus® TMS system is the only one that provides me with the consistent precision I require when treating depression. Many have relied on either medication or therapy and this offers an innovative option on the road to recovery.”
Dr. Liker adds: “The ability to noninvasively target critical brain pathways associated with a variety of diseases offers extremely exciting potential treatment avenues”
Mikko Karvinen, CEO of Nexstim, said: “We are extremely happy that BrainStim Centers decided to order a second system. The clinic is relatively new and started depression treatments successfully with Nexstim SmartFocus® TMS in spring. We are proud to be part of their story. This is a great example how our unique business model helps to grow both our customer’s business as well as ours.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com